Drugs / Apomivir®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01677689 | May 2026 → May 2027 expected | influenza | Far East Bio-Tec Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Apomivir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01677689 ↗ |
| Route | Oral | “Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.” NCT01677689 ↗ |